BRCA1 and cancer: If cancer cells harbor BRCA1/2 gene mutations and another DNA repair pathway is impeded by PARPase inhibitors, such as Olaparib, then both DNA repair pathways are blocked, leading to cancer cell death due to untimely DNA repair.